RxDoctor Payments Data

Gillian Treadwell, MD

Ophthalmology · Winston Salem, NCNPI 1205178688

Payments from drug & device makers

$2,246in general payments, 2019–2025

Across 21 payments — averaging $106.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$342
  • NEW World Medical,inc.$146
  • Johnson & Johnson Surgical Vision, Inc.$145
  • Aerie Pharmaceuticals, Inc.$129
  • Omeros Corporation$114
  • plus $206 from 3 others

What the payments were for

  • Travel & lodging$66630%
  • Food & beverage$1,58070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,246 in reported general payments places this provider in the 55th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$90,141
Medicare patients
317
Services billed
1,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost243$105,106
RhopressaNetarsudil Mesylate146$59,854
LumiganBimatoprost62$43,181
CombiganBrimonidine Tartrate/Timolol48$19,595
Latanoprost1,948$18,315
SimbrinzaBrinzolamide/Brimonidine Tart52$15,583
Methazolamide53$14,890
Travoprost109$13,625
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat964$12,609
VyzultaLatanoprostene Bunod41$12,179
Brimonidine Tartrate637$11,932
Alphagan PBrimonidine Tartrate31$11,456
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol81$8,810
RestasisCyclosporine12$7,382
Timolol Maleate373$4,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$129$164,959389 claims
AbbVieLumigan, Combigan, Alphagan P, Restasis$342$81,614153 claims
AlconSimbrinza$1,164$15,58352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →